Ependymoma Drug Market
Global Ependymoma Drug Market Size, Share & Trends Analysis Report by Type (Abemaciclib, Indoximod, Afatinib Dimaleate, Alisertib, G-207, and Others), By Application (Hospital, Clinic, and Others) Forecast 2022-2028
The global ependymoma market is anticipated to grow at a significant CAGR of 4.7% during the forecast period. The rising prevalence of brain tumor and cancer cases is the major factor driving the growth of the market. According to the American Society of Clinical Oncology (ASCO), ependymoma occurs most often in young children, accounting for around 5% of all childhood brain cancers. Around 240 children and young adults under the age of 19 in the US will be diagnosed with ependymoma in 2021. The 5-year survival rate for children and teens with ependymoma in the US from birth to age 19 is 83%. In addition, ependymomas occur with the same incidence in both men and women, however, the incidence of ependymoma variables is higher in men than in women. However, the alternative treatment options of treating tumors and cancer, like chemotherapy is expected to restrain the growth of ependymoma drug market during the forecast period. This report will further analyse all the factors that are directly or indirectly impacting the growth of the global ependymoma drug market.
Impact of COVID-19 Pandemic on Global Ependymoma Drug Market
The COVID-19 pandemic had significantly impacted the ependymoma drug market as the diagnosis and treatment of various diseases, including cancer and tumors were postponed during the initial period of the pandemic. Furthermore, the research activities were also slow-downed as scientists were involved in the rapid development of vaccine and medicine for the treatment of COVID-19. As the situation got normalized, the market of ependymoma had bounced back as the backlog treatment were started in hospitals. This report will further provide an in-depth analysis of the impact of COVID-19 on the global ependymoma drugs market.
Segmental Outlook
The global ependymoma drug market is segmented based on the type and application. Based on the type, the market is segmented into abemaciclib, indoximod, afatinib dimaleate, alisertib, G-207, and others. Based on the application, the market is sub-segmented into the hospital, clinic, and others. Among these, the clinic segment is anticipated to propel the growth of the market during the forecast period. The above-mentioned segments can be customized as per the requirements.
Global Ependymoma Drug Market Share by Type, 2021 (%)
The Indoximod Segment is Anticipated to Hold a Prominent Share in the Global Ependymoma Drug Market
Indoximod segment is anticipated to hold the largest share in the market. Indoximod is developed to block the enzymatic pathway of IDO (indoleamine 2,3-dioxygenase). It is essential for the natural regulation of immune responses. The powerful immune system is implicated in controlling the immune response to various mechanisms such as infection, organ transplants, the immune system, and cancer. By blocking the IDO pathway, it estimates that indoximod will enhance antitumor antibodies and slow down tumor growth. Due to this immense biological importance the demand for indoximod drugs will remain high during the forecast period.
Regional Outlooks
The global ependymoma drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The market can also be analyzed for a particular region or country level as per the requirement.
Global Ependymoma Drug Market Growth, by Region 2022-2028
The North America Region Holds the Major Share in the Global Ependymoma Drug Market
The North American region holds the major share in the global ependymoma drugs market due to the high prevalence of ependymoma in this region. According to the Collaborative Ependymoma Research Network, ependymomas account for about 1.9% of all tumors found in adults of the US over 20 years of age. Additionally, an estimated 1,100 of the US adults are diagnosed with ependymoma every year. In addition, ependymomas account for 5.7% of all tumors found in children of the US aged 0-14 years and an estimated 185 children diagnosed with ependymoma per year.
The Asia-Pacific region is expected to see significant growth in the ependymoma drugs market due to the growth of the medical tourism industry. In addition, the increase in purchasing power and the rapidly expanding health care infrastructure are expected to further fuel the growth of the ependymoma drugs market in the region during the forecast period.
Market Players Outlook
The major companies serving the global ependymoma drug market include Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Amgen Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2021, Moleculin Biotech, Inc. had received FDA approval for the novel p-STAT3 inhibitor WP1066, used for the treatment of patients with rare brain and spinal cord malignancy, ependymoma.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global ependymoma drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Ependymoma Drug Market
- Recovery Scenario of Global Ependymoma Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Amgen Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Boehringer Ingelheim GmbH
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Bristol-Myers Squibb Co.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Cavion LLC
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Key Strategy Analysis
3.6. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Ependymoma Drug Market by Type
4.1.1. Abemaciclib
4.1.2. Indoximod
4.1.3. Afatinib Dimaleate
4.1.4. Alisertib
4.1.5. G-207
4.1.6. Others
4.2. Global Ependymoma Drug Market by Application
4.2.1. Hospital
4.2.2. Clinic
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Advantage Inc.
6.2. Celgene Corp.
6.3. Eli Lilly & Co.
6.4. Millennium Pharmaceuticals Inc
6.5. NewLink Genetics Corp
6.6. Ono Pharmaceutical Co Ltd.
1. GLOBAL EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ABEMACICLIB EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL INDOXIMOD MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL AFATINIB DIMALEATE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL ALISERTIB MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL G-207 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OTHERS EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
9. GLOBAL HOSPITAL EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL CLINIC EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL OTHERS EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. NORTH AMERICAN EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. NORTH AMERICAN EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. EUROPEAN EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. EUROPEAN EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
22. REST OF THE WORLD EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. REST OF THE WORLD EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
24. REST OF THE WORLD EPENDYMOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL EPENDYMOMA DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL EPENDYMOMA DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL EPENDYMOMA DRUG MARKET, 2021-2028 (%)
4. GLOBAL EPENDYMOMA DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL ABEMACICLIB EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL INDOXIMOD EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL AFATINIB DIMALEATE EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL ALISERTIB EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL G-207 EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL OTHERS EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL EPENDYMOMA DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
12. GLOBAL HOSPITAL EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL CLINIC EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL OTHERS EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL EPENDYMOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. US EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. UK EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD EPENDYMOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
